| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 53.54 | 6.6% |
| Total Income | 53.54 | 6.6% |
| Expenditure | 58.24 | 32.9% |
| PBT | -8.93 | 246.2% |
| Net Profit | -9.05 | 248.1% |
| OPM | -8.77% | 32.34pp |
| NPM | -16.91% | 27.57pp |
| EPS | -0.03 | 200.0% |
Akebia Therapeutics Reports Q1 2026 Financial Results
07 May 2026 · 7 May, 4:42 pm
Summary
Akebia Therapeutics reported its financial results for the first quarter ended March 31, 2026. Vafseo net product revenues grew to $15.8 million. Total revenues were $53.5 million, a decrease from $57.3 million in the same quarter of the previous year, driven by lower Auryxia revenues. The company reported a net loss of $9.1 million, compared to a net income of $6.1 million in Q1 2025. Akebia's cash and cash equivalents stood at $162.6 million as of March 31, 2026.
Key Highlights
- 1
Akebia's Vafseo net product revenues grew to $15.8 million in Q1 2026.
- 2
Total net product revenues for Q1 2026 reached $52.0 million.
- 3
The number of patients treated with Vafseo increased by 60% in Q1 2026 compared to Q4 2025.
- 4
The total number of prescribers increased to approximately 1,025 in Q1 2026, representing a 28% increase over Q4 2025.
- 5
Total revenues were $53.5 million in the first quarter of 2026, compared to $57.3 million in the first quarter of 2025.
- 6
Net loss was $9.1 million in the first quarter of 2026, compared to net income of $6.1 million in the first quarter of 2025.
- 7
Cash and cash equivalents as of March 31, 2026, were approximately $162.6 million.
Management Comments
John P. Butler
“The number of patients on Vafseo increased through the start of the year, and we are further encouraged by trends suggesting continued growth as we leverage improved patient access and adherence as dialysis organizations implement observed dosing protocols. Increasing the breadth and depth of Vafseo prescribing, complemented by our efforts to generate data that will potentially demonstrate its additional clinical benefits, is critical to achieving our goal to make Vafseo standard of care for patients on dialysis. Separately, I’m pleased with the progress made to advance our clinical pipeline of kidney disease programs, now with two clinical programs enrolling, including a Phase 2 clinical trial of praliciguat in FSGS. We remain on track with plans to initiate a Phase 2 open-label rare kidney disease basket study in the second half of 2026, evaluating AKB-097 in IgA nephropathy, lupus nephritis and C3 glomerulopathy. These efforts were recently highlighted as part of our virtual R&D Day, where key medical experts reinforced the potential of our expanding pipeline.”
Informational and educational content only. Not investment advice.